The Technion, founded in 1912, is Israel’s oldest university. It offers undergraduate and graduate degrees in science and engineering, and related fields such as architecture, medicine, industrial management and education. It has 18 academic departments and about 60 research centers. Since its founding, Technion has awarded over 107,000 degrees. Its faculty includes three Nobel Laureates. Technion graduates head more than half of the Israeli companies traded on NASDAQ, and nearly three-quarters of managers in Israel’s electronic industries hold Technion degrees. The 2016 Shanghai Ranking placed Technion 69th in the index of the world’s leading academic institutions, and the top position for any Israeli institute. Many innovations in all fields of science, technology, engineering and life sciences have their origins in research conducted at the Technion. A recent survey by MIT ranked the Technion in sixth place worldwide for innovation and entrepreneurship.
Main tasks in the project:
We study drugs for treatment of traumatic brain injury, stroke, and neurodegenerative disease, and inflammation (quite successfully). Technion will be mainly involved in WP7 and 8, thanks to their technological expertise in drug study programs and development of formulations, targeting brain disorders as they relate to the young. It will participate also in WP2, WP3, WP4, WP5 and WP6.